Relmada Therapeutics (NASDAQ:RLMD) & Sandoz Group (OTCMKTS:SDZNY) Financial Analysis

Relmada Therapeutics (NASDAQ:RLMD) and Sandoz Group (OTCMKTS:SDZNY) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings and dividends.

Profitability

This table compares Relmada Therapeutics and Sandoz Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-269.49%	-205.22%
Sandoz Group	N/A	N/A	N/A

Insider & Institutional Ownership

45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 0.1% of Sandoz Group shares are held by institutional investors. 20.7% of Relmada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Relmada Therapeutics and Sandoz Group, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1	0	1	0	2.00
Sandoz Group	0	2	0	1	2.67

Relmada Therapeutics presently has a consensus target price of $10.00, indicating a potential upside of 150.00%. Given Relmada Therapeutics’ higher possible upside, research analysts clearly believe Relmada Therapeutics is more favorable than Sandoz Group.

Earnings & Valuation

This table compares Relmada Therapeutics and Sandoz Group”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$79.98 million	($1.80)	-2.22
Sandoz Group	$10.36 billion	3.00	$1.00 million	N/A	N/A

Sandoz Group has higher revenue and earnings than Relmada Therapeutics.

Volatility & Risk

Relmada Therapeutics has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, Sandoz Group has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Summary

Sandoz Group beats Relmada Therapeutics on 6 of the 11 factors compared between the two stocks.

About Relmada Therapeutics

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

About Sandoz Group

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.